Indication
Endometrioid Adenocarcinoma
Aliases
Fallopian Tube Endometrioid Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Fallopian Tube Endometrioid Adenocarcinoma
25 clinical trials
26 products
10 drugs
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial CancersStatus: Recruiting, Estimated PCD: 2024-08-01
Product
STRO-002Clinical trial
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)Status: Terminated, Estimated PCD: 2020-08-24
Product
NivolumabProduct
RucaparibClinical trial
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Terminated, Estimated PCD: 2022-09-27
Drug
AtezolizumabProduct
EmactuzumabDrug
TiragolumabClinical trial
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-09
Clinical trial
Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805Status: Recruiting, Estimated PCD: 2024-06-30
Drug
AN0025Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor TherapyStatus: Withdrawn, Estimated PCD: 2023-03-17
Product
CopanlisibClinical trial
A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial CarcinomaStatus: Recruiting, Estimated PCD: 2026-04-30
Product
IpilimumabProduct
OlaparibProduct
PaclitaxelProduct
TopotecanClinical trial
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2027-03-17
Clinical trial
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262Status: Active (not recruiting), Estimated PCD: 2015-12-01
Product
BevacizumabProduct
CarboplatinDrug
GemcitabineProduct
IpatasertibProduct
Oncolytic Measles VirusClinical trial
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2022-07-07
Clinical trial
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-07-31
Product
TremelimumabClinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AbraxaneClinical trial
FRαDCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian CancerStatus: Recruiting, Estimated PCD: 2027-07-15
Product
PembrolizumabClinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Product
CediranibClinical trial
Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionStatus: Recruiting, Estimated PCD: 2025-12-01
Product
PegcetacoplanClinical trial
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)Status: Active (not recruiting), Estimated PCD: 2019-04-30
Drug
DocetaxelClinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2019-09-12
Product
CabozantinibClinical trial
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-21
Product
Anetumab RavtansineClinical trial
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2028-02-09
Product
TolinapantClinical trial
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)Status: Recruiting, Estimated PCD: 2024-09-01
Product
PeposertibClinical trial
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
olaparibClinical trial
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
CapivasertibClinical trial
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2026-12-30
Drug
mFOLFOX6Clinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Drug
LurbinectedinDrug
T-VEC